Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07510048 · ClinicalTrials.gov registry record · Phase 2

Combatting HIV Or Other STIs Early (CHOOSE)

A Phase 2 study, sponsored by Westat.

Not yet
Registry status
Phase 2
Development phase
200
Enrollment target

NCT07510048: Clinical Trial Phase 2 study, sponsored by Westat.

NCT07510048 is a Phase 2 study that has not yet begun recruiting, run by Westat. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07510048, a Phase 2 study, has not yet begun recruiting, sponsored by Westat.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target

Study Summary

The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people. It is hypothesized that PrEP Choice will improve HIV PrEP uptake and adherence among young people and will be cost-effective to deliver to young people in the United States (U.S.). This study will also assess the uptake, adherence, and acceptability of DoxyPEP among young people.

Primary Outcome

1\. PrEP uptake; the proportion of participants receiving PrEP from the study site within 9 months of study follow-up. PrEP uptake is binary, indicating whether the study participant has received PrEP from the study site. This endpoint compares the proportion of participants who receive PrEP from the study site within the first 9 months of study follow-up between the treatment arms.

Interventions

  • OTHER Standard of care and PrEP Choice at Enrollment
  • OTHER Standard of care followed by PrEP Choice at Month 9

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2026-04
Est. Completion 2029-09
Phase Phase 2
Westat

13 total trials

What is known before NCT07510048 opens enrollment

NCT07510048 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).

The record links to 0 conditions, and to 2 interventions - of which Standard of care and PrEP Choice at Enrollment is the first listed.

NCT07510048 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07510048 about?

NCT07510048 is a clinical study titled "Combatting HIV Or Other STIs Early (CHOOSE)". The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people. It is hypothesized that PrEP Choice will improve HIV PrEP uptake and adherence among young people and wi...

What is the current status of trial NCT07510048?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-04. Estimated completion is 2029-09.

What interventions are being tested in trial NCT07510048?

The interventions under investigation include: Standard of care and PrEP Choice at Enrollment (OTHER), Standard of care followed by PrEP Choice at Month 9 (OTHER).

Who is sponsoring clinical trial NCT07510048?

This trial is sponsored by Westat, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07510048's enrollment target sits among peer trials

200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07510048, the US trial registry maintained by the National Library of Medicine. NCT07510048 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.